Literature DB >> 18223028

Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts.

Jodie L Guy1, Daniel W Lambert, Anthony J Turner, Karen E Porter.   

Abstract

The renin-angiotensin system (RAS), in particular angiotensin II, plays an important role in cardiac remodelling. Angiotensin-converting enzyme (ACE) and angiotensin-converting enzyme 2 (ACE2) are key players in the RAS and act antagonistically to regulate the levels of angiotensin II. In this study, we reveal the functional expression of ACE2 in human cardiac myofibroblasts, cells that are essential to the maintenance of normal cardiac architecture and also play a key role in myocardial remodelling. The observed reciprocal expression of ACE and ACE2 in these cells may reflect the possible opposing activity of these two enzymes. In this study, we demonstrate the presence of ACE2 as an ectoenzyme and reveal that ACE2 undergoes phorbol-12-myristate-13-acetate-inducible ectodomain shedding from the membrane. When cells were exposed to a number of pathophysiological stimuli, modulation of ACE2 levels was not detected. Importantly, whilst we found ACE2 to be expressed constitutively in cardiac myofibroblasts there were no detectable levels in either vascular smooth muscle cells or vascular endothelium, indicating that ACE2 expression is not ubiquitous. In paraffin sections of atrial appendage tissue, we observed a distinct staining pattern for ACE2 which appeared different from that of ACE. In conclusion, this study is the first to report co-expression of ACE and ACE2 in human cardiac myofibroblasts and may therefore present a model primary system for study of the comparative cell biology of ACE2 and ACE and their potentially opposing roles in myocardial remodelling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223028     DOI: 10.1113/expphysiol.2007.040139

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  10 in total

1.  Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.

Authors:  Zhili Shao; Kevin Shrestha; Allen G Borowski; David J Kennedy; Slava Epelman; James D Thomas; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09       Impact factor: 5.712

Review 2.  Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.

Authors:  Michikado Iwata; Randy T Cowling; Seon Ju Yeo; Barry Greenberg
Journal:  J Mol Cell Cardiol       Date:  2010-12-13       Impact factor: 5.000

3.  Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling.

Authors:  Nicola E Clarke; Martin J Fisher; Karen E Porter; Daniel W Lambert; Anthony J Turner
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

4.  New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.

Authors:  Anderson J Ferreira; Tatiane M Murça; Rodrigo A Fraga-Silva; Carlos Henrique Castro; Mohan K Raizada; Robson A S Santos
Journal:  Int J Hypertens       Date:  2012-01-26       Impact factor: 2.420

Review 5.  Advances in research on ACE2 as a receptor for 2019-nCoV.

Authors:  Jie Wu; Wei Deng; Shumin Li; Xiuhong Yang
Journal:  Cell Mol Life Sci       Date:  2020-08-11       Impact factor: 9.261

6.  Activation of Kinin B1R Upregulates ADAM17 and Results in ACE2 Shedding in Neurons.

Authors:  Rohan Umesh Parekh; Srinivas Sriramula
Journal:  Int J Mol Sci       Date:  2020-12-25       Impact factor: 5.923

Review 7.  ACE2 Nascence, trafficking, and SARS-CoV-2 pathogenesis: the saga continues.

Authors:  Sally Badawi; Bassam R Ali
Journal:  Hum Genomics       Date:  2021-01-29       Impact factor: 4.639

Review 8.  Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation.

Authors:  Robin Augustine; Abhilash S; Ajisha Nayeem; Shaheen Abdul Salam; Priya Augustine; Pan Dan; Pablo Maureira; Fatima Mraiche; Carmine Gentile; Philip M Hansbro; Lana McClements; Anwarul Hasan
Journal:  Chem Biol Interact       Date:  2021-11-03       Impact factor: 5.192

9.  Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites.

Authors:  Thomas L Williams; Gregory Strachan; Robyn G C Macrae; Rhoda E Kuc; Duuamene Nyimanu; Anna L Paterson; Sanjay Sinha; Janet J Maguire; Anthony P Davenport
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

Review 10.  ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives.

Authors:  Federica Saponaro; Grazia Rutigliano; Simona Sestito; Lavinia Bandini; Barbara Storti; Ranieri Bizzarri; Riccardo Zucchi
Journal:  Front Mol Biosci       Date:  2020-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.